Abstract
Background Treatment resistant depression (TRD) is one of the leading causes of disability in Canada and is associated with significant societal costs. Repetitive transcranial magnetic stimulation (rTMS) is an approved, safe, and well-tolerated intervention for TRD. In the setting of the COVID-19 pandemic, reducing the number of visits to the clinic is a potential approach to significantly minimize exposure and transmission risks to patients. This can be accomplished by administering multiple treatment sessions in a single day, using an rTMS protocol known as accelerated intermittent theta burst stimulation (aiTBS). The objective of this novel study is to assess the feasibility, acceptance and clinical outcomes of a practical high-dose aiTBS protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with unipolar depression previously responsive to electroconvulsive therapy (ECT) or patients warranting ECT due to symptom severity.
Methods All patients with unipolar depression referred to the brain stimulation service at the Centre for Addiction and Mental Health (CAMH) who warrant ECT will be offered screening to assess for eligibility to enroll in this trial. This open label, single group trial consists of 3 phases. In the acute treatment phase, treatment will occur 8 times daily for 5 days a week, until symptom remission is achieved or a maximum of 10 days of treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks, followed by 1 treatment day per week for 2 weeks. Patients will then enter the symptom-based relapse prevention phase including virtual check-ins and a treatment schedule based on symptom level. Remission, response and change in scores on several clinical measures from baseline to the end of the acute, tapering and relapse prevention phases represent the clinical outcomes of interest.
Discussion Findings from this novel clinical trial may provide support for the use of aiTBS, including tapering treatments and symptom-based relapse prevention treatments, as a safe and effective alternative intervention for patients needing ECT during the COVID-19 pandemic.
Trial registration Clinicaltrials.gov: NCT04384965
Competing Interest Statement
DMB has received research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in kind equipment support for an investigator initiated study from Brainsway Ltd. He is the site principal investigator for three sponsor initiated studies for Brainsway Ltd. He also receives in kind equipment support from Magventure for investigator initiated research. He received medication supplies for an investigator initiated trial from Indivior. FVR receives research support from Canadian Institutes of Health Research, Brian Canada, Michael Smith Foundation for Health Research, Vancouver Coastal Health Research Institute, and in kind equipment support for investigator initiated trial from MagVenture. He has participated in an advisory board for Janssen. JD has received research support from the Arrell Family Foundation, the Buchan Family Foundation, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Canadian Institutes of Health Research (CIHR), the Klarman Family Foundation, NIH, the Ontario Brain Institute, the Toronto General and Western Hospital Foundation, and the Weston Family Foundation; he has received travel stipends from Lundbeck and ANT Neuro; he has served as an advisor for BrainCheck, Restorative Brain Clinics, and TMS Neuro Solutions. ZJD has received research support from the Ontario Mental Health (OMH) Foundation, the CIHR, the Brain and Behaviour Research Foundation, and the Temerty family and Grant family through the CAMH Foundation and the Campbell Institute. ZJD has received research and equipment in kind support for an investigator initiated study through Brainsway Inc., and a travel allowance through Merck. ZJD has also received speaker funding through Sepracor Inc., and AstraZeneca, served on advisory boards for Hoffmann La Roche Limited and Merck, and received speaker support from Eli Lilly. DBL, MG, TK, YK, GK, APT, DV and CRW report no competing interests.
Clinical Trial
Clinicaltrials.gov: NCT04384965
Funding Statement
This work is supported by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario (grant no. 1000890)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Centre for Addiction and Mental Health Research Ethics Board has reviewed this study and has granted approval REB number 059/2020
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The final dataset generated from the current protocol will be available from the corresponding author on reasonable request
Abbreviations
- aiTBS
- accelerated intermittent theta burst stimulation
- ATHF
- Antidepressant Treatment History Form
- BDI-II
- Beck’s Depression Inventory
- CAMH
- Centre for Addiction and mental Health
- CGI-S and CGI-I
- clinician global impression severity and improvement
- DLPFC
- dorsolateral prefrontal cortex
- eCRF
- electronic case report forms
- ECT
- Electroconvulsive therapy
- FDA
- Food and Drug Administration
- fMRI
- functional Magnetic Resonance Imaging
- GAD-7
- Generalized Anxiety Disorder 7-Item
- HRSD
- Hamilton Rating Scale for Depression
- ITT
- intention to treat
- MDD
- Major depressive disorder
- MINI
- Mini-International Neuropsychiatric Interview
- RMT
- resting motor threshold
- NMS
- Neurological, Mental and Substance Use disorders
- PHQ-9
- Patient Health Questionnaire
- RA
- research analyst
- rTMS
- repetitive transcranial magnetic stimulation
- SSI
- Scale of Suicidal Ideation
- STABLE
- Symptom-Titrated Algorithm-based Longitudinal ECT
- TASS
- Transcranial Magnetic Stimulation Adult Safety Screen
- TRD
- treatment-resistant depression
- WHODAS
- World Health Organization Disability Assessment Schedule
